Get ready! The initial public offering (IPO) for Anthem Biosciences Limited is set to open its doors for subscription on July 14, offering investors a new opportunity to participate in this innovation-driven biotech company. Here’s a detailed look at everything you need to know about the upcoming IPO.
Anthem Biosciences IPO: Dates to Mark
The subscription window for the Anthem Biosciences IPO will kick off on Monday, July 14. This three-day period provides potential investors with time to make their move.
Mark your calendars, as the subscription will officially close on Wednesday, July 16. It’s a short window, so prompt action is advised for those interested.
Price and Allocation Details
The company has set the price band for its equity shares between Rs 540 and Rs 570 per share. This range gives investors a clear idea of the cost per share.
Ahead of its public opening, Anthem Biosciences successfully allocated 1.78 crore equity shares to 60 anchor funds. This pre-IPO allocation was made at the upper end of the price band, Rs 570 apiece, successfully raising Rs 1,016 crore.
Who Are the Anchor Investors?
A host of prominent investors participated in the anchor book, showing strong confidence in Anthem Biosciences. Notable names include Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, and Amundi Funds.
Indian financial institutions also played a significant role, with HDFC MF, ICICI Prudential MF, Axis MF, UTI MF, Quant MF, and Motilal Oswal MF among the key participants.
Important Dates for Investors
For those eagerly awaiting the outcome, the allotment of shares for the Anthem Biosciences IPO is slated for July 17. This is when successful applicants will find out if they’ve been allocated shares.
Following the allotment, the shares of Anthem Biosciences Limited are expected to be listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) around July 21.
Behind the Scenes: Key Facilitators
KFin Technologies Limited has been appointed as the official registrar for the Anthem Biosciences IPO, handling all the administrative aspects of the share sale.
The IPO is being steered by a strong consortium of book running lead managers, including JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory and Securities (India) Private Limited.
Additionally, HDFC Bank Limited and ICICI Bank Limited are serving as the sponsor banks for this significant public offering.
Understanding Anthem Biosciences
Anthem Biosciences is known as an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO). Their operations are fully integrated, covering everything from drug discovery and development to manufacturing.
The company also specializes in manufacturing and selling complex, specialized fermentation-based Active Pharmaceutical Ingredients (APIs). Their product range includes vital components like probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
- Anthem Biosciences IPO opens July 14 and closes July 16.
- The price band is fixed at Rs 540-Rs 570 per equity share.
- The company raised Rs 1,016 crore from anchor investors.
- Share allotment is expected on July 17, with listing around July 21.
With these details in hand, potential investors can now make informed decisions regarding Anthem Biosciences’ entry into the public market.
